Form 4: Phathom Pharmaceuticals Director Frank Karbe Receives Equity Compensation Package

Phathom Pharmaceuticals, Inc. Director Frank Karbe was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Summary

• On June 3, 2025, Frank Karbe, a Director of Phathom Pharmaceuticals, Inc. (PHAT), acquired 10,500 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0 and are part of the Issuer's Non-Employee Director Compensation Program.
• The RSUs are set to vest 100% on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, whichever occurs first, contingent on Mr. Karbe's continued service on the Board.
• Following this transaction, Mr. Karbe beneficially owns 67,500 shares of Common Stock.
• Additionally, on June 3, 2025, Mr. Karbe was granted 17,500 stock options with an exercise price of $4.95 per share.
• These options also vest on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, whichever occurs first, subject to his continued Board service.
• The stock options have an expiration date of June 2, 2035.
• After this transaction, Mr. Karbe beneficially owns 17,500 derivative securities in the form of stock options.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects a standard and expected compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The equity grants align the interests of Director Frank Karbe with those of the shareholders, as his compensation is tied to the company's stock performance.
• The grants are part of a standard Non-Employee Director Compensation Program, indicating a structured approach to executive incentives.

Future Outlook

The future outlook for the granted equity is tied to the vesting schedule, which is contingent upon the director's continued service on the Board through the first anniversary of the grant date or the next annual meeting of stockholders.

Management Comments

• The Restricted Stock Units and stock options were granted pursuant to the Issuer's Non-Employee Director Compensation Program.

Industry Context

The granting of equity compensation, such as Restricted Stock Units and stock options, to non-employee directors is a common practice across the biotechnology and pharmaceutical industries. This method is widely used to attract and retain experienced board members while aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The structure of granting RSUs and stock options to non-employee directors is a standard compensation practice observed in many publicly traded companies, particularly within the life sciences sector.
• The vesting schedule, typically tied to continued service over one year or until the next annual meeting, is also a common feature designed to ensure ongoing commitment from board members.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The Restricted Stock Units and stock options are expected to vest on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, subject to Frank Karbe's continued service.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership